RESUMEN
The discovery of potent and selective inhibitors of VZV based on unusual bicyclic alkyl furo pyrimidine nucleosides has been recently reported. Modifications to the side-chain by addition of a phenyl group were found to further enhance the antiviral potency of these compounds. A series of alkoxyphenyl compounds (5a-5g) and two halophenyl derivatives (5h and 5i) were successfully synthesised and displayed anti-VZV activity at low microM concentrations.
Asunto(s)
Antivirales/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Herpesvirus Humano 3/efectos de los fármacos , Nucleósidos de Pirimidina/farmacología , Antivirales/síntesis química , Compuestos Bicíclicos Heterocíclicos con Puentes/síntesis química , Nucleósidos de Pirimidina/síntesis químicaAsunto(s)
Antivirales/síntesis química , Antivirales/farmacología , Arabinonucleósidos/síntesis química , Arabinonucleósidos/farmacología , Herpesvirus Humano 3/efectos de los fármacos , Nucleósidos de Pirimidina/síntesis química , Nucleósidos de Pirimidina/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/síntesis química , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Células Cultivadas , Fibroblastos/virología , HumanosRESUMEN
Bicyclic furano pyrimidine nucleosides have been found to be highly potent and selective inhibitors of varicella zoster virus (VZV). They are inactive against herpes simplex virus and have been known for several decades as (unwanted) synthetic by-products in the Pd-catalysed coupling of acetylenes to 5-iodo nucleosides. These fluorescent bicyclic nucleosides are now established as a new family of potent antivirals. They are unusual in that they exhibit complete specificity for VZV and require an alkyl (or alkylaryl) side-chain for biological activity. The latter requirement confers extremely high lipophilicities on these compounds, unknown amongst chemotherapeutic nucleosides, which may be of considerable importance in formulation, dosing and tissue distribution. The most potent compounds reported are p-alkylaryl compounds, with EC50 values below 1 nM versus VZV and selectivity index values of around 1,000,000. Here, we review the discovery, synthesis, characterization, antiviral profile, SAR, mechanism of action and development prospects for this new family of antivirals.
Asunto(s)
Antivirales/química , Antivirales/farmacología , Furanos/farmacología , Herpesvirus Humano 3/efectos de los fármacos , Nucleósidos de Pirimidina/química , Nucleósidos de Pirimidina/farmacología , Antivirales/síntesis química , Desoxirribosa/química , Furanos/síntesis química , Furanos/química , Espectroscopía de Resonancia Magnética , Nucleósidos de Pirimidina/síntesis química , Solubilidad , Espectrometría de Fluorescencia , Especificidad por SustratoRESUMEN
In addition to our recent report on the potent anti-varicella-zoster virus (VZV) activity of some unusual bicyclic furopyrimidine nucleosides bearing long alkyl side chains, we herein report the further significant enhancement of the antiviral potency by inclusion of a phenyl group in the side chain of these compounds. The target structures were prepared by the Pd-catalyzed coupling of a series of para-substituted arylacetylenes with 5-iodo-2'-deoxyuridine, to give intermediate 5-alkynyl nucleosides which were cyclized in the presence of Cu to give the desired bicyclic systems. The compounds display extraordinary potency and selectivity for VZV; the most active are ca. 10 000 times more potent than the reference compound acyclovir and ca. 100 times more potent than the alkyl analogues earlier reported by us. The current compounds show little cytotoxicity, leading to selectivity index values >/= 1 000 000. From a range of DNA and RNA viruses tested, only VZV was inhibited by these compounds indicating their extreme selectivity for this target virus. The novelty of the molecules, coupled with their extreme potency and selectivity, their desirable physicochemical properties, and their relative ease of synthesis, makes them of considerable interest for potential drug development for VZV infections.
Asunto(s)
Antivirales/síntesis química , Compuestos Bicíclicos Heterocíclicos con Puentes/síntesis química , Herpesvirus Humano 3/efectos de los fármacos , Nucleósidos de Pirimidina/síntesis química , Antivirales/química , Antivirales/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/química , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Línea Celular , Humanos , Nucleósidos de Pirimidina/química , Nucleósidos de Pirimidina/farmacología , Relación Estructura-ActividadRESUMEN
We herein report the discovery of an entirely new category of potent antiviral agents based on novel deoxynucleoside analogues with unusual bicyclic base moieties. Target structures, previously known as byproducts in Pd-catalyzed coupling of terminal alkynes with 5-iodo-nucleosides, are recognized herein for the first time to be potent and selective inhibitors of varicella-zoster virus (VZV) in vitro. As an unusual structure-activity relationship we noted the absolute requirement of a long alkyl side chain, with an optimum length of C(8)-C(10), for antiviral activity. We thus report the synthesis and characterization of a series of chain-modified analogues and their extensive in vitro evaluation. The lead compounds have a ca. 300-fold enhancement in anti-VZV activity over the reference compound acyclovir, with no detectable in vitro cytotoxicity. The novel structure of these compounds, coupled with their ease of synthesis, excellent antiviral profile, and promising physical properties, makes them of great interest for possible antiviral drug development.